Researchers reported on 1-year follow-up among patients at 2 centers, all of whom had psoriasis or psoriatic arthritis, after Brazilian health authorities issued a 2017 mandate that patients being treated with the reference infliximab be switched to CT-P13, and that new starts be given the biosimilar instead of the reference.
As more healthcare systems elect to switch patients from reference infliximab to biosimilar CT-P13 (Inflectra, Remsima), more data on the safety and efficacy of the biosimilar begin to emerge from real-world practice. While many of these data are from the European experience with CT-P13, additional data are beginning to be reported in other territories where the biosimilar has gained authorization and has entered the treatment landscape for inflammatory diseases.
One such example is a study published this month researchers from 2 centers in Brazil, where CT-P13 was authorized in 2016 by local authorities. In the study, published in Anais Brasileiros de Dermatologia, researchers reported on 1-year follow-up among patients at the 2 centers, all of whom had psoriasis or psoriatic arthritis, after Brazilian health authorities issued a 2017 mandate that patients being treated with the reference infliximab be switched to CT-P13, and that new starts be given the biosimilar instead of the reference.
The study included 36 patients who had been treated with the reference drug previously and 4 new starts who began treatment with CT-P13. Among the treatment-naïve patients, 2 had psoriatic arthritis. Among the patients who had been treated with the reference drug, 17 had psoriatic arthritis. Patients who had received the reference in the past had a mean 5 years (range, 1-16) of treatment with infliximab before the switch.
During the 1 year of follow-up, 2 patients reported mild worsening of skin lesions, but there was no significant increase in Psoriasis Area and Severity Index (PASI) score observed.
Two patients had infusion-related reactions (IRRs); one occurred in a treatment-naïve patient during the second infusion of infliximab, and the other occurred in a patient who has previous treatment with the reference, but had stopped treatment 4 months prior dur to a medication shortage. This second patient experienced the IRR during the first infusion of the biosimilar.
One patient developed tuberculosis (TB), after which treatment with infliximab was discontinued and treatment for TB was initiated.
The remaining 35 patients had no IRRs or adverse events and had controlled skin and joint symptoms. Their PASI scores ranged from 0 to 2.7.
“Studies with larger cohorts and longer follow-up are still needed,” write the authors, “but our preliminary results show that biosimilars may provide an opportunity to reduce health system costs because of their similarity to reference drugs in terms of safety and efficacy.”
Reference
Kurizky PS, Galvão LO, Martinis GA. Efficacy and safety of biosimilar infliximab CT-P13 in the treatment of psoriasis and psoriatic arthritis: 1-year follow-up. An Bras Dermatol. 2019;94(4):483-484. doi: 10.1590/abd1806-4841.20198358.
Eye on Pharma: Bevacizumab Update; Samsung Bioepis, J&J Settlement; Another EU Trastuzumab
December 6th 2023Outlook Therapeutics provides an update on the development of its bevacizumab candidate for age-related macular degeneration; Samsung Bioepis settles with Johnson & Johnson (J&J) over its ustekinumab biosimilar candidate; and the European Union gains another trastuzumab biosimilar.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Adalimumab Biosimilars Take Center Stage: A Game Changer for IBD Treatment
July 16th 2023Laura Wingate, from the Crohn's & Colitis Foundation, explains some of the challenges regarding educating patients and providers on biosimilars for inflammatory bowel disease (IBD) as well as whether the gastroenterology space is ready for the influx of adalimumab biosimilars.
Public Payer in Poland Saves €243 Million by Using Biosimilar TNF Inhibitors
November 11th 2023The use of biosimilars of tumor necrosis factor (TNF) inhibitors within Poland’s public payer saved over €243 million from 2013 to 2021, with about 68% of that coming from the rheumatic musculoskeletal diseases alone.
Real-World Data Confirm Safety, Efficacy of CT-P13 in Inflammatory Diseases
November 9th 2023A real-world analysis from Japan confirmed that CT-P13, an intravenous infliximab biosimilar, had comparable safety and efficacy to the reference product (Remicade; infliximab) in patients with immune-mediated inflammatory diseases.